Merck

Palantir Deepens Relationship With Ringier To Help It Transform Into A Digital-First, Global Media Company

Psyched: Novamind Partners With Merck, Atai Expands To Japan, Australia Funds Psychedelics Research

Barron's Picks And Pans: Bank Mergers, Comcast, Dogs of the Dow, Square And More

Psyched: Novamind Partners With Merck, Atai Expands To Japan, Australia Funds Psychedelics Research

Barron's Picks And Pans: Bank Mergers, Comcast, Dogs of the Dow, Square And More

Barron's Picks And Pans: Merck, Walmart, Zoetis And More

Benzinga's Bulls And Bears Of The Week: Apple, Ford, Merck, Uber And More

Barron's Picks And Pans: Merck, Walmart, Zoetis And More

|

Benzinga's Bulls And Bears Of The Week: Apple, Ford, Merck, Uber And More

|

Pharma Large And Mid-Caps Race Against COVID-19

|

10 International ADR Companies That Are Conducting Virtual Investor Presentations This Week

|

Sponsored

Merck Recent News

Benzinga's Bulls And Bears Of The Week: Merck, Nike, Target And More

|

Barron's Picks And Pans: GM, Kraft Heinz, Tesla, Under Armour And More

|

Bulls And Bears Of The Week: Boeing, GM, Pfizer, Starbucks And More

|

Barron's Picks And Pans: Corning, Merck, Microsoft And More

|

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

|

Barron's Picks And Pans: Gold, Energy, Dividends And More

|

Can Merck And Pfizer Beat Low Expectations?

|

Dow Earnings: High Hopes For Chevron, Johnson & Johnson

|

This Week's Dow Earnings: High Expectations For DuPont And Visa

|

Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences

|

Merck And Pfizer Earnings: Will They Beat Expectations Again?

|

Shares Of Merck Dip Lower Following Q4 Print

|

Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient

|

Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA'

|

Barron's Recap: What's Next?

|

Barron's Recap: Airline Stocks Ready To Soar

|

Bank Of America On Merck: 'MAGNIF-TECOS!'

|

Apple & Other Earnings Expected To Dominate The Week Of April 27

|

Why Johnson & Johnson's Strong Pharmaceutical Business Is A Concern

|

Merck Shares Teetering On The Brink Of A Further Downside Correction

|

Earnings Expectations For The Week Of February 2: Disney, Exxon, GM And More

|

Earnings Expectations For The Week Of October 27: Facebook, Exxon, Pfizer And Much More

|

Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level

|